長江生科(00775.HK)急漲36%創逾四個月高 全球推新冠病毒檢測試劑盒
長江生命科技(00775.HK)全球推新冠病毒檢測試劑盒,該股四連升,今早一舉升破20天、100天及50天線(0.85-0.88),最高見1.16元,創逾四個月高,現造1.06元,急升36%,成交增至1.21億股,涉資1.31億元。
長江生科公布,已與新加坡科技研究院(A*Star)簽訂許可協議,在香港以至全球分銷以CoV-2冠狀病毒逆轉錄聚合(酉每)鏈式反應「RT-PCR」進行COVID-19測試的檢測試劑盒。該檢測試劑盒由A*Star及陳篤生醫院共同研發,並已取得新加坡衛生科學局之臨時認可,並已於2020年2月以來,獲新加坡當地六家公立醫院及一家私立醫療集團採用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.